Occurrence of Pharmaceuticals and Personal Care Products in the Water Environment of Poland: A Review

Abstract

The issue of pharmaceuticals and personal care products (PPCPs) in the water environment has gained increasing interest worldwide. To determine the nature and extent of this problem for Poland, this paper presents a review of research on the presence of PPCPs in Poland, looking at results for different water samples, including wastewater (before and after treatment), landfill leachate, surface water (standing water bodies and rivers), seawater, groundwater and drinking water. The review is based on over 50 scientific articles and dissertations referring to studies of PPCPs. It also briefly outlines possible sources and the fate of PPCPs in the aquatic environment. The review of Polish research has revealed that studies have previously covered at least 39 PPCP groups (270 compounds in total). These studies focused mainly on wastewater and rivers, and only a few concerned landfill leachate and seawater. They most often reported on nonsteroidal anti-inflammatory drugs and antibiotics. The highest concentrations of the analysed PPCPs were found mainly in raw wastewater (e.g., naproxen, up to 551,960 ng/L), but they were also occasionally found in surface water (e.g., azithromycin, erythromycin, irbesartan and metoprolol) and in groundwater (e.g., N,N-diethyl-meta-toluamide, known as DEET, up to 17,280 ng/L). Extremely high concentrations of bisphenol A (up to 2,202,000 ng/L) and diclofenac (up to 108,340 ng/L) were found in landfill leachate. Although numerous substances have been detected, PPCPs are still not monitored regularly, which makes it difficult to obtain a clear understanding of their incidence in the water environment.

Recent Advances in Advanced Oxidation Processes for Degrading Pharmaceuticals in Wastewater—A Review

“…Based on their therapeutic applications, the pharmaceuticals found in wastewater mainly include antibiotics, analgesics, antidepressants, antihistamines, anti-inflammatory drugs, painkillers, cardiovascular drugs, antidyskinetic medicines, diuretic drugs, statins, anti-epileptic drugs, and antihypertensive agents [46,47]. These pharmaceuticals are commonly used to treat fever, reduce inflammation and allergic diseases, and alleviate symptoms, such as pain, headaches, cold, flu, arthritis, musculoskeletal injuries, dyskinesia and Parkinson's disease, high blood pressure, and high cholesterol, as summarized in Table 1.…”

An Overview of Degradation Strategies for Amitriptyline

“…Attention should be paid by patients not to associate AMT with alcohol or other central nervous system depressants, as this can enhance their effects [74]. Drug degradation can also raise regulatory concerns, as regulatory authorities impose strict guidelines on drug stability and quality [58,68,69,73,76]. Addressing drug degradation implications requires comprehensive stability studies during drug development and post-marketing surveillance [43,77,78].…”

Synthesis, Characterization and Application of a MIP-polyHIPE for Selective Extraction of Angiotensin II Receptor Antagonists Residues in Natural Waters

“…However, little attention has been paid to these bioactive substances compared, for instance, to antimicrobials and anti-inflammatory drugs. As documented in recent research, sartans occurrence in environmental waters ranges from tens ng L −1 up to tens µg L −1 [ 14 , 15 , 16 ]. As newly highlighted by risk assessment studies, these concentration levels are responsible for non-negligible hazardous effects, with moderate–high environmental risk assigned to IRB [ 14 ].…”